These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 10541552)

  • 1. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
    Alt JR; Greiner TC; Cleveland JL; Eischen CM
    EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.
    Schmitt CA; McCurrach ME; de Stanchina E; Wallace-Brodeur RR; Lowe SW
    Genes Dev; 1999 Oct; 13(20):2670-7. PubMed ID: 10541553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
    Jacobs JJ; Scheijen B; Voncken JW; Kieboom K; Berns A; van Lohuizen M
    Genes Dev; 1999 Oct; 13(20):2678-90. PubMed ID: 10541554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
    Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
    Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-independent functions of the p19(ARF) tumor suppressor.
    Weber JD; Jeffers JR; Rehg JE; Randle DH; Lozano G; Roussel MF; Sherr CJ; Zambetti GP
    Genes Dev; 2000 Sep; 14(18):2358-65. PubMed ID: 10995391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
    Wang J; Boxer LM
    J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIF loss impairs Myc-induced lymphomagenesis.
    Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
    Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.
    Odvody J; Vincent T; Arrate MP; Grieb B; Wang S; Garriga J; Lozano G; Iwakuma T; Haines DS; Eischen CM
    Oncogene; 2010 Jun; 29(22):3287-96. PubMed ID: 20305689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
    Lindström MS; Klangby U; Wiman KG
    Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
    Kamijo T; van de Kamp E; Chong MJ; Zindy F; Diehl JA; Sherr CJ; McKinnon PJ
    Cancer Res; 1999 May; 59(10):2464-9. PubMed ID: 10344759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor spectrum in ARF-deficient mice.
    Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
    Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
    Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
    Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.